Pick of the Week - October 5, 2025

Dr. Nicole Paulk is the CEO, Founder, and President of Siren Biotechnology and has dedicated her career to advancing the field of gene therapy. With nearly two decades of expertise, Nicole has been at the forefront of developing cutting-edge advances to propel the field of gene therapy forward for a wide range of diseases. Nicole has held various leadership positions in academia and industry and most notably was an Assistant Professor of AAV Gene Therapy in the UCSF Department of Biochemistry & Biophysics before leaving to found Siren.

Nicole has a B.S. in Medical Microbiology, a Ph.D. in Viral Gene Therapy and Regenerative Medicine from OHSU and completed her Postdoctoral Fellowship and Instructorship in Human Gene Therapy at Stanford University prior to starting her lab at UCSF.

BridgeBio Pharma (Nasdaq: BBIO)

Share price: $52.86/share (market cap: $10.1 billion)

• They have phenomenal programs and a really good management team

• They manage their money well

• They think really strategically about the biotech market

• The stock has more than doubled in the past year
  

Are you interested in buying shares of BridgeBio? EquityZen is a marketplace for private companies aspiring to transform our world - explore their investment options today.

Here’s a list of our past expert investing picks.

Small business M&A is hot. Cash-flowing SMB deals are attractive but hard to access. CapitalPad solves this and connects accredited investors directly with sponsors ready to acquire existing companies.

Offer: 10% off of fees when you start building your SMB portfolio today.

Full list of exclusive offers for AIR subscribers.

<sub>Vincent Labs, Inc. nor our featured investment expert are not in the business of rendering personalized or individualized investment advice. We don't (and can't) know your financial situation, risk tolerances, or investing objectives. Accordingly, the information provided along with the decisions made and actions taken by the Service do not constitute a recommendation that a particular portfolio, security, strategy or action taken is suitable for you, or any specific person for that matter.

Neither Vincent Labs, nor its experts, writers or presenters of content will be liable for any investment decision you make, or action you take based upon reliance on any material you read here. Vincent Labs is a company of investors writing for investors and as such, the writers (and/or the company) may own stocks, ETFs, cryptocurrencies, or other digital assets mentioned.

Vincent Labs, Inc. strongly urges caution when considering these investments and encourages you to speak with your own financial and tax advisors before investing.</sub>